Výsledky vyhledávání - "Susane Krege"

Akademický článek

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Autor: Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susane Krege, Jürgen Gschwend, Heidrun Rexer, Michael Stöckle

Publikováno v: Trials, Vol 18, Iss 1, Pp 1-9 (2017)

Abstract Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is t

Externí odkaz: https://doaj.org/article/690cf09f4623408381878b95f241dadc

Zobrazit plný text záznamu

Additional file 2: of Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Autor: Carsten-Henning Ohlmann, Jäschke, Michelle, Jaehnig, Peter, Susane Krege, Gschwend, Jürgen, Rexer, Heidrun, Stöckle, Michael

SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*. (PDF 101 kb)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87a229934f26232ed2e1e8f9e5c1d6a8

Zobrazit plný text záznamu

Additional file 1: of Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

Autor: Carsten-Henning Ohlmann, Jäschke, Michelle, Jaehnig, Peter, Susane Krege, Gschwend, Jürgen, Rexer, Heidrun, Stöckle, Michael

Trial protocol. (PDF 1322 kb)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02ddc7862c709148a731b2dd8db0a8ec

Zobrazit plný text záznamu

Autor: Jürgen E. Gschwend, Michelle Jäschke, Peter Jaehnig, Carsten-Henning Ohlmann, Heidrun Rexer, Michael Stöckle, Susane Krege

Publikováno v: Trials
Trials, Vol 18, Iss 1, Pp 1-9 (2017)

Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is the prolon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d742b887e3018b3109a943d8cf2464db
https://www.ncbi.nlm.nih.gov/pubmed/28978327

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání